Tag: CKM syndrome
-
A Preprint Estimates the 2026 CKM Guideline Newly Qualifies 7.5 Million US Adults for GLP-1 Receptor Agonists, Mostly Overweight Adults Without Comorbidity; “Zero New SGLT2 Inhibitor Candidates” Is a Product of the Comparator Definition
A Preprint Estimates the 2026 CKM Guideline Newly Qualifies 7.5 Million US Adults for GLP-1 Receptor Agonists, Mostly Overweight Adults Without Comorbidity; “Zero New SGLT2 Inhibitor Candidates” Is a Product of the Comparator Definition Analysis based on information available as of 2026-11-03. 30-second summary What: A not-yet-peer-reviewed preprint (Corsi et al., medRxiv, posted 2026-10-26) applied…
-
Finerenone across CKM stages — the relative effect is flat, the absolute benefit is not, and the new endpoint moves its own goalposts
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. The 30-second version What. A post hoc analysis of 12,990 people with type 2 diabetes and chronic kidney disease from two phase 3 trials, pooled and then re-classified using the…
